HTB50-2 Inhibits Growth and Migration of Triple-negative Breast Cancer via FOSL2/FOXC1 Signaling Axis and Subsequent Ferroptosis
Our data suggest that HTB50-2 exerts its anti-cancer properties by ferroptosis via FOSL2/FOXC1 signaling pathway. Hence, HTB50-2 has an important application potential in the treatment of TNBC.
Authors
- Yan Ji (ORCID: https://orcid.org/0009-0005-5569-3590)
- Di Ge (ORCID: https://orcid.org/0000-0003-4568-7830)
- Wenying Yin
- Lei Fang (ORCID: https://orcid.org/0000-0003-3999-7170)
- Na Liu (ORCID: https://orcid.org/0000-0001-5730-4732)
- Fengying Yang
- Wenqi Duan
- Shan Xie
- Yu-zhu Lyu
Institutions
- University of Jinan (CN)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2024-08-12
- DOI
- https://doi.org/10.2174/0109298673306760240802062909
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.42